Bayer eyes launch of heart, menopause relief drugs in 2025
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Jakhar
Published On 2025-04-08 07:00 GMT | Update On 2025-04-08 07:00 GMT
Advertisement
London: Bayer said it is gearing up to launch two new pharmaceutical products this year, each with the potential to generate more than $1 billion in annual peak sales. The move comes as the German pharmaceutical and agricultural giant looks to bolster its drug portfolio amid mounting debt challenges.
In a statement, Bayer said it is preparing to introduce Beyonttra, also known as acoramidis, a treatment aimed at a condition that results in heart failure.
In "late summer" this year, it was eyeing the launch of menopause relief drug elinzanetant to ease hot flashes, it added.
As per Reuters, it said both had blockbuster potential, an industry term for potential peak annual sales of at least $1 billion.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.